Economic evaluation data have become a key requirement in pharmaceutical reimbursement submission dossiers for many countries. While most of the data are produced for “initial launch countries,” payers from subsequent launch countries are increasingly requiring estimates that are relevant or generalizable to their own populations to be considered valid. Since cost and resource limitations prevent technology producers from conducting cost effectiveness studies in every launch country, and local assessors have their own limitations, methods for adapting these global models become highly needed.
This course will introduce methodology for adaptation of international cost-effectiveness models to local jurisdictions, providing guidance on potential model selection and key considerations from stakeholder perspectives, with reference to the ISPOR Good Practices on Economic Data Transferability Task Force. Principle methodology will be supplemented by practical case studies.